CRSP

+ Watchlist + Portfolio

CRISPR Therapeutics AG

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $55.44
52-Week Range: $44.12 – $78.48
Market Cap: $5.36B
P/E (TTM): —
EPS (TTM): -4.74
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.07
PEG Ratio: —
Return on Equity: -26.10%
Return on Assets: -14.20%
Gross Margin: 0.00%
Operating Margin: -1127.55%
Profit Margin: 0.00%
Current Ratio: 17.85
Debt/Equity: 0.45
Total Debt: $783.75M
Free Cash Flow: $-215.85M
Revenue Growth: 1041.40%
Earnings Growth: —
Enterprise Value: $3.78B

CRSP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$436.00K	$370.00M	$35.00M	$0.00
Cost of Revenue	$110.25M	$130.25M	$120.67M	$213.48M
Gross Profit	-$109.81M	$239.75M	-$85.67M	-$213.48M
Research & Development	$461.64M	$387.33M	$310.24M	$381.06M
Selling, General & Admin	$102.46M	$76.16M	$72.98M	$73.54M
Operating Expenses	$563.35M	$462.29M	$380.90M	$451.09M
Operating Income	-$673.16M	-$222.54M	-$466.57M	-$664.57M
EBITDA	-$648.99M	-$202.70M	-$447.31M	-$645.09M
Pretax Income	-$650.50M	-$150.72M	-$362.67M	-$577.97M
Income Tax	-$325.00K	$2.89M	$3.59M	$3.63M
Net Income	-$650.17M	-$153.61M	-$366.25M	-$581.60M
Diluted EPS	-8.36	-1.94	-4.34	-6.47
Diluted Shares	77.75M	79.22M	84.36M	89.93M

CRSP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$211.88M	$389.48M	$298.26M	$347.56M
Receivables	$0.00	$200.00M	$25.00M	$0.00
Current Assets	$1.85B	$1.91B	$1.94B	$1.99B
Total Assets	$2.24B	$2.23B	$2.24B	$2.27B
Current Liabilities	$121.11M	$108.79M	$87.78M	$149.12M
Total Debt	$244.02M	$238.63M	$223.69M	$206.75M
Total Liabilities	$367.58M	$346.77M	$309.95M	$343.43M
Retained Earnings	-$846.09M	-$999.70M	-$1.37B	-$1.95B
Shareholders' Equity	$1.88B	$1.88B	$1.93B	$1.92B
Working Capital	$1.73B	$1.80B	$1.85B	$1.84B

CRSP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$495.74M	-$260.38M	-$142.77M	-$345.01M
Capital Expenditure	-$37.19M	-$11.97M	-$1.90M	-$25.91M
Free Cash Flow	-$532.93M	-$272.35M	-$144.68M	-$370.93M
Depreciation & Amortisation	$24.17M	$19.84M	$19.26M	$19.48M
Stock-Based Compensation	$97.95M	$81.03M	$86.57M	$72.50M
Investing Cash Flow	-$258.65M	$374.65M	-$280.48M	-$31.80M
Financing Cash Flow	$38.59M	$62.66M	$331.98M	$426.03M
Net Change in Cash	-$715.80M	$176.94M	-$91.27M	$49.21M

CRSP Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$1.00M	$10.00M
Cost of Revenue	$57.51M	$45.15M	$57.12M	$53.70M	$45.95M	$40.27M
Gross Profit	-$57.51M	-$45.15M	-$57.12M	-$53.70M	-$44.95M	-$30.27M
Research & Development	$72.48M	$166.15M	$58.90M	$83.53M	$68.57M	$69.63M
Selling, General & Admin	$19.30M	$18.92M	$16.93M	$18.40M	$17.18M	$17.55M
Operating Expenses	$90.92M	$184.17M	$74.94M	$101.06M	$85.30M	$87.00M
Operating Income	-$148.42M	-$229.32M	-$132.06M	-$154.76M	-$130.25M	-$117.27M
EBITDA	-$143.69M	-$224.68M	-$127.63M	-$149.10M	-$125.93M	-$112.99M
Pretax Income	-$134.89M	-$207.26M	-$105.82M	-$130.00M	-$122.09M	-$90.19M
Income Tax	$1.11M	$1.29M	$619.00K	$614.00K	$839.00K	$960.00K
Net Income	-$136.00M	-$208.55M	-$106.44M	-$130.61M	-$122.93M	-$91.15M
Diluted EPS	-1.58	-2.40	-1.17	-1.37	-1.28	-0.94
Diluted Shares	85.94M	87.07M	91.31M	95.27M	96.05M	96.51M

CRSP Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$235.18M	$193.62M	$286.50M	$347.56M	$423.31M	$291.34M
Receivables	$0.00	$0.00	$0.00	$0.00	—	—
Current Assets	$1.87B	$1.73B	$1.93B	$1.99B	$2.45B	$2.37B
Total Assets	$2.17B	$2.03B	$2.25B	$2.27B	$2.73B	$2.65B
Current Liabilities	$119.45M	$104.36M	$118.96M	$149.12M	$136.29M	$132.90M
Long-Term Debt	—	—	—	—	$585.47M	$586.20M
Total Debt	$219.36M	$215.45M	$211.02M	$206.75M	$787.64M	$783.75M
Total Liabilities	$336.94M	$318.59M	$329.33M	$343.43M	$911.26M	$904.22M
Retained Earnings	-$1.50B	-$1.71B	-$1.82B	-$1.95B	-$2.07B	-$2.16B
Shareholders' Equity	$1.83B	$1.71B	$1.92B	$1.92B	$1.81B	$1.75B
Working Capital	$1.75B	$1.63B	$1.81B	$1.84B	$2.31B	$2.24B
Net Debt	—	—	—	—	$162.16M	$294.86M

CRSP Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$53.95M	-$113.88M	-$84.63M	-$92.55M	-$108.90M	-$83.50M
Capital Expenditure	-$206.00K	-$25.12M	-$74.00K	-$517.00K	-$504.00K	-$3.12M
Free Cash Flow	-$54.15M	-$139.00M	-$84.71M	-$93.07M	-$109.40M	-$86.62M
Depreciation & Amortisation	$4.74M	$4.65M	$4.43M	$5.66M	$4.32M	$4.28M
Stock-Based Compensation	$20.21M	$17.61M	$16.60M	$18.08M	$16.32M	$17.32M
Investing Cash Flow	-$19.75M	$69.98M	-$119.23M	$37.20M	-$410.74M	-$55.66M
Financing Cash Flow	$10.59M	$2.26M	$296.77M	$116.41M	$591.91M	$7.18M
Net Change in Cash	-$63.11M	-$41.65M	$92.91M	$61.06M	$72.27M	-$131.98M

Market Snapshot

About

CRISPR Therapeutics AG is a gene editing company focused on developing transformative medicines using CRISPR/Cas9 technology. Headquartered in Zug, Switzerland with U.S. operations in Cambridge, Massachusetts, the company is advancing a diverse portfolio of programs in areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. CRISPR Therapeutics gained FDA approval for Casgevy (exagamglogene autotemcel) in 2023, the first CRISPR-based gene therapy approved in the United States. The company maintains strategic partnerships with Vertex Pharmaceuticals and other leading healthcare organizations.